EML4 ‐ ALK ‐Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review
Year: 2025
Type: article
Study design: Case Report
Abstract: We report a case showing that lorlatinib is effective in treating EML4-ALK-positive low-grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4-ALK fusion and promoting new ideas for the study of EML4-ALK targets in ovarian cancer.
Source: Clinical Case Reports
DOI: 10.1002/ccr3.70043
Authors: Qiongqian Li, Tongze Cai, Xiaoming Zheng, Shunrong Zhang, Chanjuan Li, Huang Tang, Zhiyong Yu, Jianlong Zhou
Institution: Guangxi University of Chinese Medicine
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,820
OpenAlex ID: W4406187084